Clinical trial monitoring is an essential process of drug development. It is the stage where developed drugs are tested on human subjects to determine if they are effective.
Fear over the recent coronavirus outbreak continues to manifest in extreme ways. Retail stores have run out of hand sanitizers; the stock market has plunged, and healthcare institutions are overwhelmed.
The invention of new drugs relies on the ability to test and validate the research. It hasn’t exactly been smooth sailing in recent years. In fact, it’s been notoriously difficult for organizations to conduct clinical trial recruitment successfully.
China has become the most popular region for clinical trial research over the last few years. A recent case study showed clinical trials had increased by 451% between years 2010 and 2017. This increasing investment by large companies like BeiGene, Ltd. is a result of the continuing effort by Chinese regulators to improve healthcare facilities to compete on a global scope.
We are living in unprecedented times. On the 11th of March 2020, the world health organization upgraded the COVID-19 epidemic as a pandemic and different countries have implemented different ways to tackle the spread of this disease. Much of this involves social distancing especially for the vulnerable in our societies.
Immunosuppressive drugs are mandatory when a patient is going through procedures like organ or tissue transplantation, chemotherapy, or suffering from autoimmune diseases. This is because ISP drugs have a narrow therapeutic window. Fatal complications can develop using subtherapeutic doses.